Women health and the microbiota

The female urogenital tract is compromised of the vagina, cervix, ovarian system, and the bladder and plays a critical role in reproduction, and sexual and urinary function. Urogenital infections, e.g. vaginal candidiasis, bacterial vaginosis, and urinary tract infections, are very common health problems in women. The unifying feature of all of the above infections is an imbalance or dysbiosis of the natural microbiome(s); thus it follows that the healthy urogenital microbiotas play an important protective role. In fact, women with vaginal microbial dysbiosis are at higher risk of developing symptomatic infections in the vagina and/or bladder1. Multiple risk factors have been identified that can cause urogenital microbiota dysbiosis (for instance: antibiotic use, hormonal contraceptive, and vaginal lubricants).1 2 3 4

Urogenital anatomy
Figure 1. Urogenital anatomy

Both vaginal and urinary infections negatively influence patient quality of life, especially affecting self-esteem and sex life.567 As well, there appears to be further relationships within the urogenital tract, as patients with bacterial vaginosis are at an increased risk of acute urinary tract infections8, female infertility9 and also have an increased risk for complications during pregnancy10.

Urogenital Microbiomes

a The vaginal microbiome

The human vagina is colonised with microorganisms directly after birth11. The vagina is inhabited by a range of microbes from a pool of over 50 species12. The bacterial communities of healthy vaginas are mainly clustered into one of five groups: four are dominated by lactic acid-producing bacteria like Lactobacillus spp., whereas the fifth has a higher α-diversity with lower proportions of lactic acid bacteria and higher proportions of strictly anaerobic organisms1113. One of the key functions the vaginal microbiome is to keep the pH low (pH 3.8-4.2); lactobacilli and other lactic-acid producing bacteria ferment the glycogen released by the epithelial cells, which creates a selective low pH environment that inhibits growth of certain pathogenic species14 15. Pathogens and viruses are further inhibited by additional beneficial compounds produced by vaginal lactobacilli: hydrogen peroxide (H2O2), biosurfactants, and bacteriocins (which are a natural antibiotic of peptide origin). These protective vaginal compounds have even been shown to enhance the antibiotic sensitivity of vaginal pathogens to antibiotics16.

The healthy vaginal microbiota is complex and dynamic and changes during the different stages in a woman’s life. Estrogen regulates the thickening of the vaginal epithelium and the production of vaginal glycogen17. These changes in the vaginal microbiota seem to be related to estrogen levels, with increasing levels during adolescence and reproductive age. During these life phases that lactobacilli become more dominant, while they follow the declining estrogen levels in menopause. These temporal shifts in the vaginal microbiome are natural, but there are more problematic dysbiosis in the vagina microbiome can be caused by antibiotic use2, hormonal (and other) contraconceptives18 3, sexual intercourse19, vaginal lubricants4, vaginal douche17, menstruation20 21 22 23 pregnancy24 and stress25 26 27. Women with dysbiosis are likely at higher risk of developing symptomatic infections in the vagina and/or bladder, as well as having an increased risk of sexually transmitted diseases, pregnancy complications, and preterm labor1.

b The urinary microbiome

In contrary to the long-held paradigm, a healthy bladder is not sterile. New bacterial identification techniques such as 16S rRNA gene analysis and high-throughput DNA sequencing have revealed uncultured in the bladders of both healthy adult female individuals and patients with UTIs28 29 30. Current research shows that urine samples are dominated by ‬‬Lactobacillus spp. or Gardnerella spp. or by the family Enterobacteriaceae, which includes‬‬‬ Escherichia spp.‬‬, Klebsiella spp., and Proteus‬‬ spp.30 31.‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬ ‬‬‬‬‬‬‬‬‬‬In some women, there is emerging evidence that dysbiosis in the urinary bacterial community may be associated with urgency urinary incontinence, overactive bladder, and UTIs31.

The origin of bladder microorganisms has been a point of heated discussion. The urinary tract is a self-contained organ with an impermeable lining, so the current opinion is that retrograde microbial ascent is thought to be the most source of the bladder organisms. Indeed, cultures of urine-isolated microorganisms from women have been genetically identified as identical to those cultured from vaginal samples32 33 and fecal microorganisms34. Furthermore, the same causative UTI pathogen can be isolated for up to three years in adults, hinting at extra-urinary microbial reservoirs35 36. Additional support for the GI tract as one source of bladder microorganisms can also be found in some earlier studies that suggest links between the gastrointestinal microbiota and urinary health37 38 39.

Anatomy of the vulva
Figure 2: Anatomy of the vulva

Shifts in the urinary microbiome causing dysbiosis can be caused by a number of factors including medication, both short term and long-term medication30, vaginal infections32 and sexual intercourse40. It is interesting to note that antibiotics are unable to alter the receptivity of urothelial cells to adherence by pathogens39, so when complete eradication of the live functioning urinary microbes is not possible, alternatives or adjuncts should be considered.



Probiotics for Urogenital Health

A clear relationship seems to exist between a decrease in the amount of lactobacilli and risk of urogenital infections. It follows that strategies that support recovery of the microbiota can play a role in both vaginal and urinary health. Probiotic bacteria, when administered in amounts over 1.0 x108 CFU for 2 months can normalize the vaginal microbiota and help cure existing infections and prevent recurrence of BV40 reviewed in Homayouni 2014]. The positive use of probiotics has also been demonstrated for the prevention of UTIs. A meta-analysis reported a statistically significant decrease in rUTIs in adult patients given probiotics, denoted by the pooled risk ratio of 0.51 (95% CI:0.26–0.99; p = 0.05)41.

An advantage for patients is that urogenital probiotics have no reported adverse side effects effects11, can be used alongside antimicrobial treatment41, present minimal discomfort42, and can be self-administered12. It is clear that urogenital probiotics can improve quality of life and sexual health, and decrease risk of preterm birth43. In addition, the evidence from the available studies suggests that probiotics can be used as adjunct treatments to enhance antibiotic treatment 6 44 and reduce side effects6.

One of the main mechanisms of action of probiotics in the prevention and/or treatment of urogenital infections is the restoration of the natural low pH environment. It is thought that colonization is also an important factor in the prevention or treatment of vaginal infections 12,45 46 47 48 49 50 51 In addition, probiotics may offer protection through the production of biosurfactants, and co-aggregation with pathogens to block adhesion and/or displace previously adherent pathogens on epithelial cells.

While probiotics may generally have a slightly inferior therapeutic effect52 than (prophylactic) antibiotics, they present minimal negative disturbances of the microbiota with no risk of antibiotic resistance and systemic side effects. This non-chemotherapeutic role of urogenital probiotics either as an adjuvant to standard treatment or a stand-alone therapy allows a clinician to have an additional option for their patients. To achieve optimal patient care, a clinician should consider to be guided by their clinical logic and experience when weighing the available evidence in the absence of standard guidelines when evaluating probiotic as alternative options such as probiotics.


  • 1. Reid G, Charbonneau D, Erb J, Kochanowski B, Beuerman D, Poehner R, Bruce AW. Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. FEMS Immunol Med Microbiol. 2003;35(2):131-4. 2003.
  • 2. Kazi YF, et al. Investigation of vaginal microbiota in sexually active women using hormonal contraceptives in Pakistan. BMC Urol. 2012 Aug 18;12:22. doi: 10.1186/1471-2490-12-22.
  • 3. a. b. Achilles SL, et al. The complexity of contraceptives: understanding their impact on genital immune cells and vaginal microbiota. AIDS. 2013 Oct;27 Suppl 1:S5-15.
  • 4. a. b. Fashemi B et al. Effects of feminine hygiene products on the vaginal mucosal biome. Microb Ecol Health Dis. 2013 Feb 25;24.
  • 5. Bilardi JE, et al. The Burden of Bacterial Vaginosis: Women’s Experience of the Physical, Emotional, Sexual and Social Impact of Living with Recurrent Bacterial Vaginosis. PLoS ONE 2013, 8(9): e74378.
  • 6. a. b. c. Martinez RC, Franceschini SA, Patta MC, et al. Improved treatment of vulvovaginal candidiasis with fluconazole plus probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14. Lett Appl Microbiol. 2009;48(3):269-74.
  • 7. Falagas, 2006, Probiotics for Prevention of Recurrent Urinary Tract Infections in Women A Review of the Evidence from Microbiological and Clinical Studies, Drugs 2006; 66 (9): 1253-126.
  • 8. Harmanli OH, et al. Urinary tract infections in women with bacterial vaginosis. Obstet Gynecol. May 2000;95:710–2.
  • 9. Salah RM, et al. Bacterial vaginosis and infertility: cause or association? Eur J Obstet Gynecol Reprod Biol. 2013 Mar;167(1):59-63.
  • 10. Goldenberg RL, et al. The preterm prediction study: fetal fibronectin,bacterial vaginosis, and peripartum infection. NICHD Maternal Fetal Medicine Units Network. Obstet Gynecol 1996;87:656e60.
  • 11. a. b. c. Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, McCulle SL, Karlebach S, Gorle R, Russell J, Tacket CO, Brotman RM, Davis CC, Ault K, Peralta L, Forney LJ. Vaginal microbiome of reproductive-age womenProc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1.
  • 12. Cribby, 2008, VaginalMicrobiota and the Use of Probiotics, Hindawi Publishing Corporation Interdisciplinary Perspectives on Infectious Diseases, Volume 2008, Article ID 256490, 9 pages doi:10.1155/2008/256490
  • 13. van de Wijgert JH, Borgdorff H, Verhelst R, Crucitti T, Francis S, Verstraelen H, Jespers V. The Vaginal Microbiota: What Have We Learned after a Decade of Molecular Characterization? PLoS One. 2014 Aug 22;9(8):e105998.
  • 14. Linhares IM, et al. Contemporary perspectives on vaginal pH and lactobacilli. Am J Obstet Gynecol. 2010; 203:1.e1–1.e5.
  • 15. O’Hanlon DE, et al. In vaginal fluid, bacteria associated with bacterial vaginosis can be suppressed with lactic acid but not hydrogen peroxide.BMC Infectious Diseases. 2011; 11:200.
  • 16. Sgibnev A and Kremleva E. Influence of Hydrogen Peroxide, Lactic Acid, and Surfactants from Vaginal Lactobacilli on the Antibiotic Sensitivity of Opportunistic Bacteria. Probiotics Antimicrob Proteins. 2016 Nov 10. [Epub ahead of print].
  • 17. a. b. Farage M, et al. Lifetime changes in the vulva and vagina. Archives of Gynecology and Obstetrics. 2006; 273:195–202.
  • 18. Stokholm J, et al. Antibiotic use during pregnancy alters the commensal vaginal microbiota. Clin Microbiol Infect. 2014 Jul;20(7):629-35.
  • 19. Marrazzo JM. Interpreting the epidemiology and natural history of bacterial vaginosis: are we still confused? Anaerobe. 2011 Aug;17(4):186-90.
  • 20. Eschenbach DA, et al. Influence of the normal menstrual cycle on vaginal tissue, discharge, and microflora. Clinical Infectious Diseases. 2000;30:901–907.
  • 21. Smith CB, et al. Bacterial flora of the vagina during the menstrual cycle:findings in users of tampons, napkins, and sea sponges. Ann Intern Med.1982; 96:948–951.
  • 22. Onderdonk AB, et al. Quantitative assessment of vaginal microflora during use of tampons of various compositions. Applied and Environmental Microbiology. 1987; 53:2774–2778.
  • 23. Shiraishi T, et al. Influence of menstruation on the microbiota of healthy women’s labia minora as analyzed using a 16S rRNA gene-based clone library method. Japanese Journal of Infectious Diseases. 2011; 64:76–80.
  • 24. Verstraelen H, et al. Longitudinal analysis of the vaginal microflora in pregnancy suggests that L. crispatus promotes the stability of the normal vaginal microflora and that L. gasseri and/or L. iners are more conducive to the occurrence of abnormal vaginal microflora. BMC Microbiology. 2009; 9:116.
  • 25. Culhane JF, et al. Stress, bacterial vaginosis, and the role of immune processes. Current Infectious Disease Reports. 2006; 8:459–464.
  • 26. Nansel TR, et al. The association of psychosocial stress and bacterial vaginosis in a longitudinal cohort. Am J Obstet Gynecol. 2006; 194:381–386.
  • 27. Culhane J. Exposure to chronic stress and ethnic differences in rates of bacterial vaginosis among pregnant women. Am J Obstet Gynecol. 2002;187:1272–1276.
  • 28. Hilt EE, McKinley K, Pearce MM, Rosenfeld AB, Zilliox MJ, Mueller ER, Brubaker L, Gai X, Wolfe AJ and Schreckenberger PC. Urine Is Not Sterile: Use of Enhanced Urine Culture Techniques To Detect Resident Bacterial Flora in the Adult Female Bladder. J Clin Microbiol. 2014 Mar; 52(3): 871–876.
  • 29. Pierce, A. and Hart, C. 1992. Vulvovaginitis: causes and management. Archives of Disease in Childhood 67: 509–512.
  • 30. a. b. c. Thomas-White, K.J., Hilt, E.E., Fok, C., Pearce, M.M., Mueller, E.R., Kliethermes, S., Jacobs, K., Zilliox, M.J., Brincat, C., Price, T.K., Kuffel, G., Schreckenberger, P., Gai, X., Brubaker, L. and Wolfe, A.J. 2016a. Incontinence medication response relates to the female urinary microbiota. International Urogynecology Journal 27: 723-733.
  • 31. a. b. Brubaker L, Nager CW, Richter HE, Visco A, Nygaard I, Barber MD, Schaffer J, Meikle S, Wallace D, Shibata N, Wolfe AJ. Urinary bacteria in adult women with urgency urinary incontinence. Int Urogynecol J. 2014 Sep;25(9):1179-84.
  • 32. a. b. Fede, T. 1983. Vulvovaginitis in children. Clinical and Experimental Obstetrics & Gynecology 10: 118–119.33
  • 33. Pierce 1992] and fecal microorganisms
  • 34. Gorbachinsky, I., Sherertz, R., Russell, G., Krane, L.S., and Steve J. Hodges, S.J. 2014. Altered perineal microbiome is associated with vulvovaginitis and urinary tract infection in preadolescent girls. Therapeutic Advances in Urology. 6: 224–229.
  • 35. Foxman, B. 2002. Epidemiology of urinary infections: incidence, morbidity, and economic costs. American Journal of Medicine 113: 5-13.
  • 36. Russo, T.A. 1995. Chromosomal restriction fragment length polymorphism analysis of Escherichia coli strains causing recurrent urinary tract infections in young women. Journal of Infectious Diseases 172; 440–445.
  • 37. Marild S, Jodal U, Mangelus L. 1989. Medical histories of children with acute pyelonephritis compared with controls. The Pediatric Infectious Disease Journal 8: 511–515.
  • 38. Pisacane A, Graziano L, Mazzarella G, Scarpellino B, Zona G. 1992. Breast-feeding and urinary tract infection. Journal of Pediatrics 120: 87–99.
  • 39. a. b. Cayan, S., Doruk, E., Bozlu, M., Duce, M., Ulusoy, E. and Akbay, E. 2001. The assessment of constipation in monosymptomatic primary nocturnal enuresis. International Urology and Nephrology 33: 513–516.
  • 40. a. b. Remis RS, Gurwith MJ, Gurwith D, Hargrett-Bean NT, Layde PM. Risk factors for urinary tract infection. Am J Epidemiol. 1987 Oct;126(4):685-94.
  • 41. a. b. Reid, G., Bruce, A.W., McGroarty, J.A., Cheng, K.J. and Costerton, J.W. 1990. Is there a role for lactobacilli in prevention of urogenital and intestinal infections? Clinical Microbiology Reviews 3: 335–344.
  • 42. Antonio MA1, Meyn LA, Murray PJ, Busse B, Hillier SL. Vaginal colonization by probiotic Lactobacillus crispatus CTV-05 is decreased by sexual activity and endogenous Lactobacilli. J Infect Dis. 2009 May 15;199(10):1506-13
  • 43. Brotman RM1, Shardell MD, Gajer P, Fadrosh D, Chang K, Silver MI, Viscidi RP, Burke AE, Ravel J, Gravitt PE. Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. Menopause. 2014 May;21(5):450-8.
  • 44. Reid, 2006, Probiotics to prevent the need for, and augment the use of, antibioticsCan J Infect Dis Med Microbiol Vol 17 No 5 September/October 2006
  • 45. Anukam KC, Osazuwa E, Osemene GI, Ehigiagbe F, Bruce AW, Reid G. Clinical study 
comparing probiotic Lactobacillus GR-1 and RC-14 with metronidazole vaginal gel to treat. 
symptomatic bacterial vaginosis. Microbes and infection / Institut Pasteur 2006;8:2772-6.
  • 46. Delia A, Morgante G, Rago G, Musacchio MC, Petraglia F, De Leo V. [Effectiveness of oral administration of Lactobacillus paracasei subsp. paracasei F19 in association with vaginal suppositories of Lactobacillus acidofilus in the treatment of vaginosis and in the prevention of recurrent vaginitis].
  • 47. Minerva Ginecol 2006;58:227-31. 

  • 48. Mastromarino P, Macchia S, Meggiorini L, et al. Effectiveness of Lactobacillus-containing vaginal tablets in the treatment of symptomatic bacterial vaginosis. Clin Microbiol Infect 2009;15:67-74.
  • 49. Petricevic L, Witt A. The role of Lactobacillus casei rhamnosus Lcr35 in restoring the normal vaginal flora after antibiotic treatment of bacterial vaginosis. BJOG 2008;115:1369-74. Ehrstrom S, Daroczy K, Rylander E, et al. Lactic acid bacteria colonization and clinical outcome after probiotic supplementation in conventionally treated bacterial vaginosis and vulvovaginal candidiasis. Microbes and infection / Institut Pasteur 2010;12:691-9. 

  • 50. Rossi A, Rossi T, Bertini M, Caccia G. The use of Lactobacillus rhamnosus in the therapy of bacterial vaginosis. Evaluation of clinical efficacy in a population of 40 women treated for 24 months. Archives of gynecology and obstetrics 2010;281:1065-9. 

  • 51. Ya W, Reifer C, Miller LE. Efficacy of vaginal probiotic capsules for recurrent bacterial 
vaginosis: a double-blind, randomized, placebo-controlled study. Am J Obstet Gynecol 
2010;203:120 e1-6. 

  • 52. Beerepoot 2012